97 results on '"di Grazia, C."'
Search Results
2. Enhancing the diagnosis of maxillary transverse discrepancy through 3-D technology and surface-to-surface superimposition. Description of the digital workflow with a documented case report
3. Small bowel intussussception due to metastatic melanoma of unknown primary site. Case report
4. Biliodigestive fistulae and gallstone ileus;diagnostic and therapeutic considerations. Our experience
5. Risk management in surgery
6. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
7. Subcutaneous low-dose IL-2 for remission maintenance in elderly acute myeloid leukemia patients
8. High prevalence of hepatitis G virus infection in Hodgkin's disease and B-cell lymphoproliferative disorders: Absence of correlation with hepatitis C virus infection
9. Imatinib for chronic myeloid leukaemia relapsing after allogeneic bone marrow transplantation
10. MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1: PROSPECTICAL EVALUATION AND MRD DIRECTED THERAPY
11. SECOND TRANSPLANTATION FOR PRIMARY GRAFT FAILURE, FOLLOWING HAPLOIDENTICAL GRAFTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
12. Rituximab treatment of Epstein-Bar virus reactivation after alternative donor transplants
13. Treatment of acute graft-versus-host disease with low-dose, alternate-day antithymocyte globulin
14. Pre-emptive therapy of Epstein-Barr virus (EBV) reactivation after allogeneic hematopoietic stem cell transplant (HSCT) with four courses of i.v. cydofovir: A single centre experience
15. HIGH PROGNOSTIC VALUE OF PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT BY COMBINED WT1 EXPRESSION AND FLOW CYTOMETRY IN ACUTE MYELOID LEUKEMIA PATIENTS
16. PONATINIB FOR RELAPSE AFTER ALLOGENEIC TRANSPLANTATION IN BCR-ABL plus LEUKEMIAS: PRELIMINARY DATA ON SAFETY AND EFFICACY
17. PREDICTING CHRONIC GRAFT VERSUS HOST DISEASE AND MORTALITY ON DAY+100 AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
18. The contribution of art-therapy and physiotherapy as complementary therapies for bone marrow transplant patients during isolation: the Magnolia Project
19. Allogeneic bone marrow transplantation in patients with hematological malignancy using busulfan, thiotepa, fludarabine as conditioning regimen
20. Thiotepa-based conditioning regimens for allogeneic stem cell transplants: long-term outcome of 374 patients with a median age of 48, grafted from related or unrelated donors
21. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions
22. Reduction of transplant related mortality with time: major improvement for patients allografted with early disease
23. Low mortality rate after diagnosis of invasive aspergillosis in 33 cord blood transplant recipients using direct intrabone injection
24. Long term follow up of the thiotepa 10+ cyclophosphamide 100 conditioning regimen in HLA identical sibling transplants
25. Molecular relapse of acute lymphoblastic leukaemia after allogeneic haematopoietic stem cell transplantation can be successfully treated with donor lymphocyte infusions
26. Total body irradiation and total marrow irradiation for patients with advanced haematologic malignanices undergoing an allogeneic stem cell transplant: a pilot study
27. LIVER IRON CONCENTRATION AND STIFFNESS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES
28. CYTOGENETIC AND MOLECULAR RISK FACTORS AT DIAGNOSIS ARE OVERCOME BY WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
29. Reduced-intensity conditioning (thiotepa plus cyclophosphamide) and rabbit anti-thymocyte globulin for alternative donor transplants
30. Donor lymphocyte infusions (DLI) for mixed chimerism in patients with severe aplastic anemia
31. Prevention of graft versus host disease with Ig M enriched immunoglobulins: a preliminary analysis of a randomized study
32. Successful non-invasive management of late-onset haemorrhagic cystitis in intrabone cord blood transplant recipients
33. Is timing of anti-thymocyte globulin (ATG) - Pre and post-hematopoietic stem cell transplants (HSCT) - Relevant for graft vs. host disease (GvHD)?
34. Toxicity and efficacy of 409 donor lymphocyte infusions for treatment of relapse after allogeneic bone marrow transplantation
35. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients
36. A predictive score for transplant related mortality (TRM) following allogeneic stem cell transplantation: day+7 serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cells dose
37. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation
38. Predicting chronic graft-versus-host disease on day+100 after allogeneic stem cell transplantation
39. Changes in airway responsiveness to methacholine following haematopoietic stem cell transplantation
40. Fast immune recovery following unmanipulated haploidentical BMT with post-transplant high-dose cyclophosphamide as GvHD prophylaxis: a comparison with siblings, unrelated donors, cord blood
41. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft
42. MFC-MRD assessment may drive post induction consolidation in intermediate risk AML. Is it time for MRD-DRIVEN approach?
43. Allogeneic hemopoietic stem cell transplantation for patients with myelodisplastic syndrome: The effect of blast count and disease status at transplant
44. Allogeneic hemopoietic stem cell transplantation for patients with lymphoma
45. CHRONIC GRAFT VERSUS HOST DISEASE: HOW MUCH DO WE NEED TO PREVENT RELAPSE?
46. Impact of HLA disparity on GvHD and relapse rate in haploidentical transplants followed by high dose post-transplant cyclophosphamide
47. UNMANIPULATED HAPLOIDENTICAL MARROW TRANSPLANTATION WITH A MODIFIED POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) REGIMEN: AN UPDATE OF THE GENOVA-ROME GEMELLI EXPERIENCE
48. Improved outcome of alternative donor transplants in patients with myelofibrosis
49. Graft Versus Host Disease and Relapse Free Survival in 470 Patients With Aml or Raeb Grafted from Sibling, Unrelated or Haploidentical Donors
50. Hemorrhages following allogeneic HSCT: incidence and impact on transplant outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.